Genome engineering is a process of insertion, deletion, modification or replacement of Deoxyribonucleic acid (DNA) bases in an organism. There are two types of gene therapy, Ex-Vivo gene therapy and In-Vivo gene therapy. Ex-vivo gene therapy involves the transfer of genes in cultured cells and then reintroducing in patient, while in In-vivo gene therapy, genes are directly delivered in cells of a particular tissue. Key companies such as CRISPR Therapeutics AG, Editas Medicine, Inc., and Intellia Therapeutics, Inc. are focusing on developing In-Vivo and Ex-vivo gene therapy. Major techniques used in genome engineering are Clustered regularly interspaced short palindromic repeats (CRISPR), Transcription activator-like effector nucleases (TALEN), and Zinc-finger nucleases (ZFNs). These are innovative genome editing tools that enable researchers to edit parts of the genome by adding, removing, or altering sections of the DNA sequence. CRISPR is an accurate, faster, and cheaper technique for editing DNA as compared to other methods such as TALEN and ZFN. Transcription activator-like effector nucleases (TALEN) is a technology widely used in live cell gene editing. Zinc-finger nucleases (ZFNs) is an artificial restriction enzyme, which simplifies targeted editing of genome by creating double-strand breaks in DNA at user-specified locations.
Market Dynamics
Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth over the forecast period. Key players in market are focusing on strategic collaborations, in order to increase their product offerings. For instance, in February 2018, Kite Pharma, Inc., a Gilead Sciences, Inc. company, collaborated with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. would use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide ribonucleic acid (RNA) products for CRISPR genome engineering.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 47 market data tables and 42 figures on "Global Irritable Bowel Syndrome Market” - forecast to 2030
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients